Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Moxifloxacin
Drug ID BADD_D01501
Description Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.
Indications and Usage For the treatment of sinus and lung infections such as sinusitis, pneumonia, and secondary infections in chronic bronchitis. Also for the treatment of bacterial conjunctivitis (pinkeye).
Marketing Status approved; investigational
ATC Code J01MA14; S01AE07
DrugBank ID DB00218
KEGG ID D08237
MeSH ID D000077266
PubChem ID 152946
TTD Drug ID D0ZV0Z
NDC Product Code 65977-0038; 51407-321; 63629-8357; 0378-5430; 65862-840; 72189-321; 16714-643; 50090-6357; 55111-112; 70518-3713; 80425-0239; 50090-5833; 53002-2723; 68180-421; 61919-553; 72789-233; 60505-0582; 68180-422; 72189-334; 17478-519; 31722-845; 0904-6406; 12527-0517; 50090-3147
UNII U188XYD42P
Synonyms Moxifloxacin | 1-Cyclopropyl--7-(2,8-diazabicyclo(4.3.0)non-8-yl)-6-fluoro-8-methoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid | Octegra | Proflox | Moxifloxacin Hydrochloride | Avelox | Avalox | Izilox | Actira | BAY 12-8039 | BAY 12 8039 | BAY-12-8039 | BAY 128039 | BAY-128039 | BAY128039
Chemical Information
Molecular Formula C21H24FN3O4
CAS Registry Number 151096-09-2
SMILES COC1=C2C(=CC(=C1N3CC4CCCNC4C3)F)C(=O)C(=CN2C5CC5)C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Prothrombin time ratio decreased13.01.02.040--Not Available
Prothrombin time ratio increased13.01.02.041--Not Available
Pruritus23.03.12.0010.000296%
Pulmonary embolism24.01.06.001; 22.06.02.001--Not Available
Pyrexia08.05.02.0030.000135%
Rash23.03.13.001--Not Available
Rash erythematous23.03.13.029--Not Available
Rash pruritic23.03.13.030--Not Available
Red blood cell count decreased13.01.05.007--Not Available
Renal failure20.01.03.005--Not Available
Respiratory distress22.02.01.012--Not Available
Restlessness19.11.02.002; 17.02.05.021--
Retinal detachment12.01.04.004; 06.09.03.003--
Rhabdomyolysis15.05.05.002--
Sensory loss17.02.07.007--Not Available
Serum sickness12.02.08.004; 10.01.03.004--
Skin discolouration23.03.03.005--Not Available
Sleep disorder19.02.04.001--Not Available
Somnolence19.02.05.003; 17.02.04.006--
Speech disorder22.12.03.027; 19.19.02.002; 17.02.08.003--Not Available
Stevens-Johnson syndrome23.03.01.007; 12.03.01.014; 11.07.01.005; 10.01.01.0450.000135%
Stomatitis07.05.06.005--
Suicidal ideation19.12.01.003--
Suicide attempt19.12.01.004--
Swelling08.01.03.015--Not Available
Swelling face08.01.03.100; 23.04.01.018; 10.01.05.018--Not Available
Swollen tongue23.04.01.014; 07.14.02.003; 10.01.05.015--Not Available
Syncope02.11.04.015; 24.06.02.012; 17.02.04.008--
Tachycardia02.03.02.007--Not Available
Tendon disorder12.01.07.019; 15.07.01.002--Not Available
The 8th Page    First    Pre   8 9 10 11    Next   Last    Total 11 Pages